Yount SE - Search Results

1

Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ^©).

Kaiser K, Yount SE, Martens CE, Webster KA, Shaunfield S, Sparling A, Peipert JD, Cella D, Rottinghaus ST, Donato BMK, Wells R, Tomazos I. Kaiser K, et al. Among authors: yount se. Patient Prefer Adherence. 2020 Apr 5;14:705-715. doi: 10.2147/PPA.S233830. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32308375 Free PMC article.

2

Mucositis in head and neck cancer: economic and quality-of-life outcomes.

Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Peterman A, et al. J Natl Cancer Inst Monogr. 2001;(29):45-51. doi: 10.1093/oxfordjournals.jncimonographs.a003440. J Natl Cancer Inst Monogr. 2001. PMID: 11694566

3

Methods and progress in assessing the quality of life effects of supportive care with erythropoietin therapy.

Yount S, Lai JS, Cella D. Yount S, et al. Curr Opin Hematol. 2002 May;9(3):234-40. doi: 10.1097/00062752-200205000-00010. Curr Opin Hematol. 2002. PMID: 11953670 Review.

4

Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index.

Yount S, Cella D, Webster K, Heffernan N, Chang C, Odom L, van Gool R. Yount S, et al. J Pain Symptom Manage. 2002 Jul;24(1):32-44. doi: 10.1016/s0885-3924(02)00422-0. J Pain Symptom Manage. 2002. PMID: 12183093 Free article.

5

Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.

Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH; Eastern Cooperative Oncology Group. Eton DT, et al. Among authors: yount se. J Clin Oncol. 2003 Apr 15;21(8):1536-43. doi: 10.1200/JCO.2003.07.128. J Clin Oncol. 2003. PMID: 12697878 Clinical Trial.

6

What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN).

Cella D, Paul D, Yount S, Winn R, Chang CH, Banik D, Weeks J. Cella D, et al. Cancer Invest. 2003;21(4):526-35. doi: 10.1081/cnv-120022366. Cancer Invest. 2003. PMID: 14533442

7

Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).

Yount S, Cella D, Banik D, Ashraf T, Shevrin D. Yount S, et al. Health Qual Life Outcomes. 2003 Nov 21;1:69. doi: 10.1186/1477-7525-1-69. Health Qual Life Outcomes. 2003. PMID: 14633279 Free PMC article.

8

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. Eton DT, et al. Among authors: yount se. J Clin Epidemiol. 2004 Sep;57(9):898-910. doi: 10.1016/j.jclinepi.2004.01.012. J Clin Epidemiol. 2004. PMID: 15504633

9

Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Yost KJ, et al. Among authors: yount se. Breast Cancer Res Treat. 2005 Apr;90(3):295-8. doi: 10.1007/s10549-004-5024-3. Breast Cancer Res Treat. 2005. PMID: 15830143

10

Measurement and management of health-related quality of life in lung cancer.

Davis K, Yount S, Wagner L, Cella D. Davis K, et al. Clin Adv Hematol Oncol. 2004 Aug;2(8):533-40. Clin Adv Hematol Oncol. 2004. PMID: 16163227 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters